Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2016

View Archived Issues

[11C]GSK-1482160: a PET radiotracer for imaging P2X7 receptors in neuroinflammation

Cell Medica and Baylor collaborate on next-generation cellular immunotherapies

Cancer Moonshot 2020 program forms the Melanoma and Sarcoma Working Group

Novartis initiates phase I/Ib study of LSZ-102 in ER-positive breast cancer

OxiGENE changes company name to Mateon Therapeutics

New rexinoid shows promise for the treatment of obesity and diabetes

Novira Therapeutics patents anti-HBV compounds

Array BioPharma and Celgene report JAK inhibitors

Intra-Cellular Therapies presents PDE2A inhibitors

Inovio Pharmaceuticals cleared to begin first phase I trial of Zika vaccine

Nivolumab evaluated for metastatic uterine leiomyosarcoma, colorectal cancer and ovarian cancer

Ipafricept plus carboplatin and paclitaxel well tolerated in phase Ib trial

FDA clears Sangamo BioSciences' IND for SB-913

EUROSTARS grant supports development of APO-010 for multiple myeloma

Afstyla available in U.S. for hemophilia A

Mitsubishi Tanabe Pharma submits NDA for edaravone for ALS

ApeX Therapeutics files IND for phase I trial of APX-3330 for pancreatic ductal adenocarcinoma

First-in-human results for the novel oral RAF inhibitor HM-95573

Takeda begins phase IIb trial for norovirus vaccine

New phase I trial studies UCART-19 in pediatric patients with B-ALL

Enanta starts phase I trial pan-genotypic cyclophilin inhibitor for HCV

FDA approves Rayaldee for secondary hyperparathyroidism in CKD

FDA approves use of Procleix Zika virus blood screening assay under IND study protocol

Inhibition of TGF-beta signaling to treat myelofibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...